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ABSTRACT: Apelin signaling plays an important role during embryo development and regulates angiogenesis,
cardiovascular activity, and energy metabolism in adulthood. Overexpression and hyperactivity of this signaling
pathway is observed in various pathologic states, such as cardiovascular diseases and cancer, which highlights the
importance of inhibiting apelin receptor (APJ); therefore, we developed a cell-based screening assay that uses
fluorescence microscopy to identify APJ antagonists. This approach led us to identify the U.S. Food and Drug
Administration–approved compoundprotamine—alreadyusedclinically after cardiac surgery—as an agent to bind
toheparinand thereby reverse its anticlottingactivity.Protaminedisplaysa390-nMaffinity forAPJandbehavesasa
full antagonist with regard to G protein and b-arrestin–dependent intracellular signaling. Ex vivo and in vivo,
protamine abolishes well-known apelin effects, such as angiogenesis, glucose tolerance, and vasodilatation.
Remarkably, protamineantagonist activity is fully reversedbyheparin treatmentboth invitroand invivo. Thus, our
results demonstrate a new pharmacologic property of protamine—blockade of APJ—that could explain some
adverse effects observed in protamine-treated patients. Moreover, our data reveal that the established anti-
angiogenic activity of protamine would rely on APJ antagonism.—Le Gonidec, S., Chaves-Almagro, C., Bai, Y.,
Kang,H. J., Smith,A.,Wanecq,E.,Huang,X.-P., Prats,H.,Knibiehler,B.,Roth,B.L., Barak,L. S.,Caron,M.G.,Valet, P.,
Audigier, Y., Masri, B. Protamine is an antagonist of apelin receptor, and its activity is reversed by heparin.
FASEB J. 31, 2507–2519 (2017). www.fasebj.org
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Apelin signaling is involved in a wide range of physio-
logic functions, participating in regulation of cardiovas-
cular and body fluid homeostasis, aswell as in the control
of energy metabolism (1). Apelin receptor, also named
APJ [putative receptorprotein related to the angiotensin II
type 1a receptor (AT1aR)], is a classAGPCR,which shares
31% sequence identity with AT1aR (2). Its endogenous
ligand, apelin, is aprepropeptideof 77 aa,whichgives rise,
after proteolytic cleavage, to apelin 36, apelin 17, apelin 13,
and the pyroglutaminated form pyro-apelin 13 (3, 4). All
apelin fragments inhibit forskolin-induced cAMP pro-
duction (5, 6); activate different intracellular effectors, such
as ERKs, PI3K/Akt, and AMPK; and trigger b-arrestin
recruitment to APJ (7–10), thereby promoting cell metab-
olism, survival, proliferation, and migration. Recently,
a second endogenous peptide ligand of APJ, named
Elabela/Toddler, hasbeen identified andobserved toplay
a crucial role in normal heart and vasculature develop-
ment during embryogenesis (11, 12).
WhereasElabela/Toddler ismainly expressed inhuman
embryonic stem cells and in the adult kidney and prostate
(13, 14), apelin and its receptor are widely expressed in
mammalian organisms (15). They are also expressed in
various brain regions that are known to regulate food
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intake, glucose, and fluid homeostasis, the highest expres-
sion detected in hypothalamic nuclei (16, 17). Moreover,
apelin possesses neuroprotective effects in the CNS (18, 19).
At theperipheral level, apelin’seffectsonenergymetabolism
have been extensively described (20). In particular, apelin
infusion improves glucose tolerance anddecreases glycemia
by stimulating glucose uptake in skeletal muscle and adi-
pose tissue, thereby improving insulin sensitivity (8, 21).
In the cardiovascular system, apelin acts as a potent
inotropic agent and reduces cardiac loading (22). More-
over, intravenous infusion of apelin in humans induces an
NO-dependent arterial vasodilatation (23), which reduces
mean arterial blood pressure. Of interest, this effect is
abolished in APJ–deficient mice (24). In addition, apelin
displays all the properties of an angiogenic factor by pro-
moting proliferation and migration of endothelial cells
(10, 25).
Inaddition to itsphysiologic functions, apelin signaling is
also associatedwith cardiovascular andmetabolic diseases,
such as atherosclerosis (26, 27), hypertension (28), and type
2 diabetes (29). Furthermore, overexpression and hyperac-
tivityof apelin signalingare linkedwithdifferentpathologic
states that promote neoangiogenesis. Indeed, in the retina,
apelin transcripts and proteins are significantly increased
during development of retinal vascular diseases and dia-
betic retinopathy (30, 31). Of note, apelin concentrations in
the vitreous of patients strictly parallel proliferative diabetic
retinopathy and the extent of vessel proliferation (32). In-
travitreal injection of an APJ antagonist—apelin F13A
peptide analog—strongly reduces the gene and protein
expression of glial fibrillary acidic protein and the an-
giogenic factor, VEGF, in the retina of diabetic rats (30).
As with many GPCRs (33), expression of APJ and its
cognate ligand apelin is also up-regulated in several can-
cers (34–37). Furthermore, serum and tumor apelin levels
positively correlate with tumor progression and poor
overall survival (35, 38, 39). Indeed, APJ expression me-
diates survival and migration of tumor cells (35, 37),
whereas apelin expression promotes tumor neoangio-
genesis (34, 38, 40), lymphangiogenesis, and lymph node
metastasis (41).
Accordingly,APJantagonists couldrepresent interesting
clinical molecules for blocking increased activity of apelin
signaling in pathologic angiogenesis.
To date, few compounds with antagonist activity on
APJ have been identified (42, 43). We thus developed a
fluorescence-based, high-throughput screening and iden-
tified the U.S. Food and Drug Administration (FDA)–
approvedcompound,protamine,which isusedaftercardiac
surgery to reverse the anticlotting effect of heparin. Byusing
different biophysical and in vitro approaches, we demon-
strate that protamine displays a 390-nM affinity forAPJ and
fully abolishes apelin-induced G-protein activation and
b-arrestin recruitment. Similarly, protamine fully inhibits
well-described in vivo effects of apelin, such as angiogenesis,
vasodilatation, and glucose tolerance. Of interest, all these
antagonist effects are completely reversed by heparin. Thus,
these results clearly demonstrate that protamine inhibits
activation ofAPJ and therefore represents a promising drug




Abs to anti–phospho-p44/42 MAPK (4370, clone D13.14.4E),
anti–phospho-S473 Akt (4060, clone D9E), anti-Akt (4691, clone
C67E7), and horseradish peroxidase–conjugated secondary Abs
were from Cell Signaling Technology (Montigny-le-Bretonneux,
France). Abs to anti-ERK2 (sc-154, clone C-14) was from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Pyro-apelin 13 (ex-
cept as otherwise indicated, pyro-apelin 13 was the only apelin
fragment used in the different experiments) and apelin 12 were
from Bachem (Bubendorf, Switzerland). Apelin 13-TAMRA
(5-carboxytetramethylrhodamine), Elabela 11, Elabela 22, and
Elabela 32 were from Proteogenix (Oberhausbergen, France).
Angiotensin II was from Sigma-Aldrich (St. Louis, MO, USA).
Injectable solutions of protamine sulfate (Protamine Choay;
Supplemental Table 1) and heparin sodium (Héparine Choay)
were obtained from Sanofi (Paris, France). Coelenterazine
h was purchased from Promega (Madison, WI, USA) and
Bandeiraea simplicifolia isolectin B4 conjugated to FITC, VEGF,
and poly-D-lysine hydrobromide were from Sigma-Aldrich.
[125I]-Apelin-13 was obtained from Phoenix Pharmaceuticals
(Burlingame, CA, USA).
Mice
All procedures were performed in accordance with institutional
guidelines foranimal researchandwereapprovedbythe INSERM
Animal Care and Use Committee. Male C57Bl/6J mice (15 wk
old; for oral glucose tolerance test and in vivo blood pressure
measurement), and female Balb/c mice (9 wk old; for the tumor
growth model) were obtained from Charles River Laboratory
(L’Arbresle, France). Mice were conventionally housed in a con-
stant temperature (20–22°C)andhumidity (50–60%)animal room,
with a 12-h light/dark cycle and free access to food and water.
Cell culture and transfections
HEK293T and U2OS cell lines were purchased from the Ameri-
can Type Culture Collection (Manassas, VA, USA) and cultured
in DMEM or minimum essential medium, respectively, supple-
mented with 10% fetal calf serum (FCS), 2 mM L-glutamine,
100 U/ml penicillin, and 100 mg/ml streptomycin (Thermo
Fisher Scientific, Waltham, MA, USA) in a 5% CO2 humidified
incubator at 37°C. All cells were tested for mycoplasma on ini-
tial culture by using a Mycoprobe Mycoplasma detection kit
(CUL001B; R&D Systems, Minneapolis, MN, USA) according to
the manufacturer’s instructions. No mycoplasma-positive cells
were used in this work.
Stable and transient transfections were realized by using a
calcium phosphate protocol according to the manufacturer’s
protocol (Thermo Fisher Scientific).
To generate U2OS cells that stably expressed human APJ
(hAPJ) and b-arrestin 2–green fluorescent protein (GFP), U2OS
cells were cotransfected with the plasmids pREN-hAPJ and
pEGFP-b-arrestin2 and selected to permanently express hAPJ
and b-arrestin 2 by using geneticin (400 mg/ml) and zeocin
(200mg/ml).U2OScellswere thenkept inculturewith200mg/ml
geneticin and 100 mg/ml zeocin.
For bioluminescence resonance energy transfer (BRET)
experiments, HEK293T cells were transiently transfected with
pEYFP-b-arrestin 2 and phRluc-hAPJ 1 d after cell seeding as
previously described (44). After transfection (24 h), cells were
plated in poly-D-lysine–coated 96-well microplates (White Opti-
Plate; PerkinElmer, Villebon-sur-Yvette, France) at a density of
100,000 cells/well in phenol red–freeminimumessentialmedium
paraformaldehyde in PBS. To determine the antagonist activity
of protamine on Elabela fragments, U2OS cells were pretreated
with protamine for 10 min, then stimulated with Elabela 11,
Elabela 22, or Elabela 32 for 1 h. Slides were mounted in fluo-
rescence mounting medium (Dako, Carpinteria, CA, USA) and
images were taken by using a Zeiss LSM-780 confocal micro-
scope (Zeiss, Jena, Germany) that was equipped with appropri-
ate laser lines and filters sets for 488 and 564 nm for fluorescence
imaging. Imageswere acquired using a363 objective anddigital
zoomset to31.4.Aminimumof 6 imageswere collected for each
sample and analyzed with Zen browser software (Zeiss).
For fluorescence-based, high-throughput assay, U2OS cells
that stably coexpressed hAPJ and b-arrestin 2-GFP were seeded
on 384-well plates (3 3 103 cells/well). Twelve hours later, cells
were starved for 1 h in phenol red–free minimum essential me-
dium, and the different compounds from the libraries were
added at a final concentration of 10 mM for 10 min before addi-
tion of apelin 13 at 10 nM final concentration. After 45 min of
stimulation at 37°C, cells were fixed with paraformaldehyde
(2% final) and images were acquired by using a Zeiss Axiovert
200 M fluorescent microscope. b-Arrestin 2-GFP aggregates
were identified by Wavelet software, which evaluated the num-
ber and intensity of fluorescent dots as previously described (45).
Radioligand binding assay
Binding experiments were performed on permanently
expressing hAPJ U2OS cells with [125I]-apelin-13 as previously
described (46). Results were analyzed with GraphPad Prism
5.0 using nonlinear regression to determine the Ki value of
protamine. [3H]-Dofetilide binding assays on human ether-a-
go-go–related gene–expressing cells were carried out as re-
ported previously by using 5 nM [3H]-dofetilide (47).
Screening of protamine on different GPCRs
Activity of protamine was assessed on Gq-coupled receptors
(angiotensin II receptor type 1, arginine vasopressin receptor 1A,
oxytocin receptor, cholinergic receptor muscarinic 1, glutamate
metabotropic receptor 1, and endothelin receptor type A ) by
using Ca2+ mobilization assay (Fluo-4 Direct Calcium Assay kit;
Thermo Fisher Scientific) and on Gi/o-coupled receptors [C-X-C
chemokine receptor type 4 (CXCR4) and cannabinoid receptor 1]
by using split luciferase assay (GloSensor cAMPassay; Promega)
according to manufacturer instructions.
Adenylyl cyclase assay
U2OS cellswere seeded onto 24-well plates (253 103 cells/well).
Forty-eight hours later, cells were washed twice with PBS, then
incubated for 15 min at 37°C in 300 ml PBS medium that con-
tained 1 mM magnesium acetate and 20 mM forskolin (Sigma-
Aldrich) in the absence or presence of different doses of apelin
13 or protaminewith apelin 13.After removal of themedium, the
reaction was stopped by addition of 500 ml of a mixture of 95%
methanol and 5% formic acid. The amount of cAMP was de-
termined on cell lysates by a radioimmunoassay performed in
mAb-coated tubes and using a [125I]-labeled cAMP tracer
(Immunotech, Thornwood, NY, USA) as described (37).
Western blot analysis
Subconfluent U2OS cells were serum-deprived for 18 h. In time
course experiments, cells were stimulated at 37°C with 100 nM
apelin 13 at different time points. For determining protamine
that contained 2% of FCS, 10mMHepes, and2mMof L-glutamine. 
Cells were then cultured for an additional 24 h before experiments.
cDNA constructs
hAPJ gene fragment was inserted into the pREN expression 
vector as previously described for murine APJ (9). For BRET 
experiments, hAPJ was amplified by PCR using pREN-hAPJ as 
template and a 59 primer (AAAGGATCCATGGAGGAAG-
GTGGTGATTTTG) that contained a BamHI restriction site and a 
39 primer (AAAGGTACCGCGTCAACCACAAGGGTCTCCT-
GGC) that contained  a  NotI restriction site. PCR product was 
cloned into a pcDNA3 vector downstream of 2 hemagglutinin 
(HA) tags, which generated amino-terminally HA-tagged hAPJ. 
Expression vector that encoded HA-hAPJ fused to Renilla lucif-
erase (Rluc) was generated as follows: the full-length coding re-
gion of hAPJ that contained HA tags without a stop codon was 
amplified by PCR by using specific primers with 59 and 39 in-
frame restriction enzyme sites of XhoI and  KpnI, respectively, and 
subcloned into humanized phRluc N3 vector (PerkinElmer). The 
vector that encodes b-arrestin 2–yellow fluorescent protein (YFP) 
has been previously described (44). AT1aR-Rluc construct was 
kindly provided by Robert J. Lefkowitz (Duke University Medical 
Center). All constructs were sequenced to check reading frame and 
integrity.
BRET measurement
For BRET assays, phenol red–free medium was removed from 
HEK293T cells and replaced by PBS that contained calcium and 
magnesium.
As previously described (44), the assay was carried out at 
room temperature and started by adding 10 ml coelenterazine h to 
the well to yield a final concentration of 5 mM. Agonist activity of 
apelin 13, angiotensin II, and protamine was measured 5 min 
after addition of the Rluc substrate, and plate reading was per-
formed 5 min after. When the assay was conducted to determine 
the antagonistic properties of protamine against apelin 13 or 
angiotensin II, protamine was added 1 min after coelenterazine h. 
Readings started 10 min after addition of Rluc substrate.
BRET signal was determined by calculating the ratio of the 
light emitted at 515–555 nm over the light emitted at 465–505 nm 
using a Mithras LB940 instrument (Berthold, Bad Wildbad, 
Germany) and filters with the appropriate band pass. Net BRET 
signals were determined by subtracting the BRET signal obtained 
with cells that only expressed Rluc-tagged hAPJ or Rluc-tagged 
AT1aR from BRET signals obtained with cells that coexpressed 
each receptor and YFP-tagged b-arrestin 2. Curves were fitted by 
using a nonlinear regression and log (agonist or inhibitor) vs. 
response fit equation using GraphPad Prism 5 (GraphPad Soft-
ware, La Jolla, CA, USA).
For time course analysis of hAPJ-b-arrestin 2 interactions, 
coelenterazine h was added 10 min before reading of samples that 
were collected at 1-s intervals for 15 min. Protamine was added 
just before reading. Apelin 13 was injected in the well 200 s later, 
and heparin was then injected 200 s after apelin 13 by using the 
Mithras microinjectors that allowed automatic delivery.
Fluorescence microscopy and screening
U2OS cells that stably coexpressed hAPJ and b-arrestin 2-GFP 
were seeded on poly-D-lysine–coated glass slides in 12-well 
dishes (3 3 105 cells/well). Twelve hours later, medium was 
replaced by fresh medium that contained no FCS, and cells 
were stimulated or not with apelin 13-TAMRA, Elabela 11, Ela-
bela 22, or Elabela 32 for 1 h, then fixed for 15 min in 4%
antagonist activity, cells were pretreated for 5 min with 1 mM
protamine, then stimulated with 100 nM apelin for 5 min or
treated with protamine alone for 10 min at 37°C. After treat-
ments, cells were washed once in ice-cold PBS and lysed for
15 min on ice as previously described (10). Proteins (20 mg) were
fractionated on 12% SDS-polyacrylamide gels and blotted to
Protran nitrocellulose membranes (Schleicher and Schuell,
Dassel, Germany). Membranes were stained with ponceau red
and sliced horizontally so that several proteins could be probed
on 1 blot. After blocking in Tris-buffered saline and Tween 20
buffer (50mMTris-HCl, pH 7.4, 150mMNaCl, and 0.2% Tween
20)with 5%nonfatmilk for 1 h at room temperature,membranes
were incubated overnight at 4°C with blocking solution that
contained the indicated Ab. Membranes were then washed and
incubated with a horseradish peroxidase–conjugated secondary
Abandhorseradishperoxidase activitywasdetected byusingan
ECL RevelBlot Plus kit (Ozyme).
Chick chorioallantoic membrane assay
Fertilized chicken eggs (E.A.R.L. Morizeau, Dangers, France)
were incubated at 37°C in a humidified chamber. At d 3 of de-
velopment, a windowwasmade in the eggshell and sealed with
Durapore tape (3M, St. Paul, MN, USA). At d 10, plastic cover-
slips (Thermanox; Thermo Fisher Scientific) that contained dried
VEGF (500 ng) or apelin 13 (50 ng) with or without 15 mg prot-
amine were deposited on the surface of the chicken embryo
chorioallantoic membrane (CAM). After 4 d of incubation, cov-
erslips and the attached CAM were excised and washed with
PBS. Blood vessels were visualized by using fluorescein-labeled
Sambucus nigra lectin (Vector Laboratories, Burlingame, CA,
USA). Images were taken by using an Eclipse E400 microscope
(Nikon,Toyko, Japan), andavascularvs. vascularizedzoneswere
quantified by using Explora Nova Morpho Expert/Mosaic
Software (Explora Nova, La Rochelle, France)
Tumor model
When protamine was administered subcutaneously, a total of
1.5 3 105 TS/A cells that overexpressed apelin [as described in
Sorli et al. (34)] were injected subcutaneously into the flank of
BALB/c syngeneic mice. From the third day after TS/A cell
injection, mice were treated with saline solution or protamine
(5000 U/kg) twice per day.
When protamine treatment was injected intravenously, the
experimental protocol was different. Mice were anesthetized
with isoflurane/oxygen inhalation (2/98%). A catheter was in-
troduced into the femoral vein, sealed under the back skin, and
externalized in the interscapular region. The surgical procedure
was carried out under aseptic conditions.Micewere individually
housedandallowed to recover for 1wk.A total of 1.53105TS/A
cells that overexpressed apelin [as described (34)] were then in-
jected subcutaneously into the flank of 9-wk-old female BALB/c
syngeneic mice. From the third day after TS/A cells injection,
mice were treated intravenously with saline solution or prot-
amine (5000 U/kg) twice per day.
For both mouse tumor models, mouse body weight and tu-
mor volume were measured 3 times/wk using the following
formula: length ☓width2 ☓p/6.
Oral glucose tolerance test
Mice were anesthetized with isoflurane/oxygen inhalation
(2/98%). A catheter was inserted into the femoral vein, sealed
under the back skin, and externalized in the interscapular region.
The surgical procedurewas carried out under aseptic conditions.
Mice were individually housed and allowed to recover for 1 wk.
All drugs were injected as a bolus of 10 ml followed by a bolus of
10 ml of saline solution. On the day of the experiment, food was
withheld from mice for 6 h. Conscious mice were intravenously
injected with protamine (10 U/kg) or saline solution. Three
minutes later and30minbeforeoral glucose load (3 g/kg), apelin
13 (200 pmol/kg) or saline solution was injected. Blood was
collected fromthe tail vein at230, 0, 15, 30, 45, 60, 90, and120min
after oral glucose load and glycemia was measured with a
glucometer (Accu-Chek Performa; Roche, Basel, Switzerland).
Blood was also collected 30 min before glucose load and 15 min
after for plasma insulin concentrations.
In vivo blood pressure measurement
using telemetry
Mice were anesthetized with isoflurane/oxygen inhalation
(2/98%), and blood pressure measurements were performed by
TA11PA-C10 transmitters (Data Sciences International, St. Paul,
MN, USA).
After shaving and disinfecting the mouse neck, the left com-
mon carotid artery was isolated. The transmitter’s catheter was
inserted into the carotid artery and pushed forward until the tip
entered the aortic arch. The transmitter’s bodywas placed under
the skin on the right flank of the mouse. For drug injections, a
catheterwas inserted into the femoral vein, sealedunder the back
skin, and externalized in the interscapular region. Mice were in-
dividually housed andallowed to recover for 1wk.On the dayof
theexperiment, foodwaswithheld frommice for6h, andanimals
were anesthetized with isoflurane/oxygen inhalation (2/98%),
andbloodpressurewasallowed to stabilize.Basalbloodpressure
was stabilized at 85.36 1.9 mmHg, and heart rate was 4756 26
beatsperminute.Micewere then injectedwithdrugsasabolusof
10 ml followed by a bolus of 10 ml of saline solution. Mice were
pretreated with saline solution or protamine (700 U/kg) or a
combination of protamine (700 U/kg) and heparin (1400 U/kg).
Three minutes later, a saline solution or apelin 12 (100 nmol/kg)
was injected. Data were recorded and analyzed by using Pone-
mah software (Data Sciences International). As previously de-
scribed (48), each animal received an intravenous injection of
angiotensin II (35 ng/kg) to determine responsiveness. Only
those that experienced a response of an increase above 20mmHg
mean arterial pressure were used for bioassays of apelin, prot-
amine, and heparin.
Statistical analysis
Results are expressed as means 6 SEM. The sample size re-
ported in each figure legend refers to the number of in-
dependently performed biologic replicates in the data set. All
data points that could be analyzed were included in statisti-
cal analyses. No statistical methods were used to pre-
determine sample size. For experimental methods that were
highly reproducible, such as oral glucose tolerance test, 7–8
biologic replicates were sufficient to detect effects of the
compounds with P , 0.05. Experimental methods with
greater variability between replicates, such as CAM assays or
tumor growth, 15–25 biologic replicates were required to at-
tain statistical significance between groups with P, 0.01. The
investigators were not blinded to allocation during experi-
ments and outcome assessment. Graphs and statistical anal-
yses were performed by using GraphPad Prism 5. Gaussian
distribution of data and equality of varianceswere testedwith
F Test and D’Agostino-Pearson normality test. Statistical tests
performedare indicated in figure legends. Sigmoid curves from
concentration-response experiments were analyzed by using
nonlinear curve fitting. Experiments were not randomized.
was detected on these receptors. Moreover, assessment
of the antagonist potency of protamine on these recep-
tors showed no effect of protamine, except for CXCR4
receptor for which protamine inhibited SDF-1a activity
by 88 6 12.4% (Fig. 1F). Conversely, protamine did not
displace binding of tritiatedDofetilide to human ether-a-
go-go–related gene potassium channel (Supplemental
Fig. 2).
Protamine antagonizes G-protein– and
b-arrestin–dependent signaling pathways
activated by apelin
We next analyzed the activity of protamine on the dif-
ferent signaling pathways that are activated by apelin.
Gi-protein–mediated cAMP inhibition is the best-
characterized response resulting from APJ activation.
Thus, we first determined the intrinsic activity of prot-
amine on cAMP production in U2OS cells that perma-
nently expressed hAPJ and b-arrestin 2-GFP. In this
assay, protamine acted as an inverse agonist on APJ,
increasing cAMP accumulation induced by forskolin
with an EC50 of 820 6 2 3 10
29 M (Fig. 2A). We then
addressed the antagonist property of protamine on
apelin-induced Gi signaling. As shown in Fig. 2B,
protamine was able to dose-dependently block apelin
effects with an IC50 of 462 6 1.7 3 10
29 M. Down-
stream Gi protein pathway, it is well established that
apelin activates ERK1/2 and Akt in different cell types
(1, 7, 9, 10). The same results were obtained in U2OS
cells that coexpressed hAPJ and b-arrestin 2-GFP,
where apelin promoted a time-dependent phosphor-
ylation of p42/p44 ERKs and Akt proteins (Fig. 2C).
Whereas protamine did not induce ERK or Akt
phosphorylation in these cells, it inhibited MAPK and
Akt activation induced by apelin (Fig. 2D).
Given the potential importance of b-arrestin–mediated
desensitization and internalization of APJ (7), we next
evaluated theeffectofprotamineonb-arrestin recruitment
to APJ. Thus, a BRET approach was developed by using
HEK293T cells that transiently coexpressed hAPJ and
b-arrestin 2 fused to their C terminus with Rluc, the BRET
donor, or YFP (the yellow variant of EGFP), the BRET
acceptor, respectively. By using real-time BRET measure-
ment in cells that expressed only hAPJ-Rluc, we observed
that apelin didnot induce BRETvariations comparedwith
PBS-treated cells; however, in cells that coexpressed hAPJ-
Rluc and b-arrestin 2-YFP, apelin rapidly increased BRET
levels, which were stable for .30 min (Fig. 2E). Apelin-
induced b-arrestin 2 recruitment to hAPJ in living cells
was dose dependent, with an EC50 of 10.76 1.23 10
29 M
(Fig. 2F). Whereas protamine did not possess any intrinsic
activity on b-arrestin 2 translocation to hAPJ as measured
by BRET, apelin activity was fully inhibited dose
dependently by protamine with an IC50 of 480.2 6 1.2 3
1029M (Fig. 2G,H). As apelin can also promote b-arrestin
1 recruitment toAPJ (7),weused the sameBRETapproach
to evaluate the activity of apelin on b-arrestin 1 re-
cruitment in our system and to determine the antagonist
activity of protamine. Apelin induced b-arrestin 1 re-
cruitment to hAPJ with an EC50 of 33.76 1.43 10
29 M in
RESULTS
Identification of protamine as an antagonist 
of APJ
To identify APJ antagonists, we engineered the human 
osteosarcoma U2OS cell line to permanently coexpress 
hAPJ and b-arrestin 2 tagged with GFP. These cells are 
large and flat and grow as a uniform monolayer, which 
makes them a useful model for fluorescence microscopy 
screening. In these cells, stimulation with a fluorescent 
apelin (apelin-TAMRA) induced formation of intracellular 
puncta composed of apelin-TAMRA/hAPJ/b-arrestin 2-
GFP (Fig. 1A). This approach is sensitive enough to 
quantify intracellular puncta induced by increasing apelin 
concentrations (Fig. 1B, C). Thus, apelin induced forma-
tion of cytosolic clusters of APJ complexes in APJ/
b-arrestin 2-GFP upon exposure to ligand with an EC50 of 
1.65 6 1.2 3 1029 M (Fig. 1C). Consequently, we set up a 
high-throughput screening assay and tested both the John 
Hopkins Drug Library that contained FDA-approved 
molecules (1514 compounds) and the combinatorial li-
brary from Tripos (50,000 compounds). Among the dif-
ferent compounds tested, we identified protamine as 
an antagonist of APJ internalization induced by apelin 
(Fig. 1B and Supplemental Table 1). In our screen, prot-
amine inhibited in a dose-dependent manner the in-
ternalization of APJ in complex with b-arrestin 2-GFP 
induced by 10 nM of apelin with an IC50 of 315.3 6 1.7 3 
1029 M (Fig. 1D). As this fluorescence-microscopy ap-
proach may produce false positives, we decided to con-
firm that APJ could bind to protamine. The affinity of 
protamine for APJ was studied by assessing its ability to 
displace [125I]-apelin-13 binding on U2OS cells that sta-
bly expressed hAPJ receptor and b-arrestin 2-GFP. We 
first determined the apparent dissociation constant Kd of 
[125I]-apelin-13 on these cells by performing saturation 
curves. Whereas [125I]-apelin-13 was unable to specifi-
cally bind to vasopressin receptor, its Kd value for 
hAPJ receptor was 0.87 3 1029 M (data not shown). In 
this assay, protamine dose-dependently inhibited spe-
cific binding of [125I]-apelin-13 (0.5 nM) with a Ki value of 
390 3 1029 M (Fig. 1E).
A new endogenous ligand of APJ, Elabela/Toddler, has 
been recently identified. We thus measured the effect of 
protamine on Elabela-induced APJ activation in U2OS 
cells that stably expressed hAPJ receptor and b-arrestin 2-
GFP. Whereas the different fragments of Elabela (Elabela 
11, Elabela 22, and Elabela 32) induce b-arrestin 2-GFP 
recruitment to APJ and its internalization, pretreatment 
with protamine fully inhibited the effects of the different 
forms of Elabela (Supplemental Fig. 1). Thus, protamine 
fully antagonized APJ activation induced by the 2 natural 
ligands of APJ, apelin and Elabela.
To analyze the possible action of protamine on other 
cell-surface receptors, the activity of protamine on differ-
ent GPCRs and ion channels was assessed. Among the 
different GPCRs tested (AT1aR, vasopressin V1a, oxytocin 
OTR, muscarinic m1R, chemokines CXCR4, metabotropic 
glutamate receptor 1, cannabinoid receptor type 1, and 
endothelin receptor type 1), no intrinsic activity of protamine
Figure 1. Identification of protamine as an antagonist of APJ. A) Confocal pictures of U2OS cells that stably expressed APJ and
b-arrestin 2-GFP stimulated with PBS (upper) or with fluorescent apelin-TAMRA (10 nM) for 1 h. Apelin-TAMRA treatment
induces internalization of APJ/b-arrestin 2-GFP in complex with apelin-TAMRA. Green channel illustrates the localization of
b-arrestin 2-GFP, whereas the red channel shows apelin-TAMRA, highlighting only internalized apelin-TAMRA. Scale bar, 10 mm.
B) Images from microscopy-based screening in 384-well plates. U2OS cells that stably expressed APJ and b-arrestin 2-GFP were
treated with PBS (left), apelin 13 (10 nM; middle), or with protamine (1 mM) and apelin 13 (10 nM; right) for 45 min. C)
Quantification of aggregates created by the formation of intracellular clusters of APJ/b-arrestin 2-GFP after a dose response of
apelin 13 in U2OS cells that stably expressed APJ and b-arrestin 2-GFP. D) Protamine dose-dependently inhibits formation
(continued on next page)
HEK293T cells that coexpressed hAPJ-Rluc and b-arrestin
1-YFP (Supplemental Fig. 3A). In addition, whereas prot-
amine had no intrinsic agonistic activity, it inhibited, in a
dose-dependent manner, apelin-induced b-arrestin 1
translocation to hAPJ, with an IC50 480 6 1.9 3 10
29 M
(Supplemental Fig. 3B, C).
Protamine is an arginine-rich basic protein that can
form a stable complex with the negatively charged hepa-
rin. To further confirm that protamine antagonism is not
mediated via itspositive charges, the effect of poly-D-lysine
on hAPJ was measured. Poly-D-lysine had no intrinsic
activity on b-arrestin 2 recruitment, and a high dose of
this positively charged polymer did not inhibit apelin-
induced b-arrestin 2 recruitment to hAPJ (Supplemental
Fig. 4A, B).
Taken together, our data demonstrate that protamine
acts as an antagonist of hAPJ by displacing apelin binding
and abrogating G-protein activation and b-arrestin
recruitment.
APJ, also called angiotensin receptor-like 1, shares
strong sequence homology with AT1aR (54% in trans-
membrane domains and 31% for the entire sequence) (1).
We previously showed that protamine does not inhibit Gq
protein activation induced by angiotensin II (Fig. 1F);
therefore, we analyzed the activity of protamine on
b-arrestin recruitment to AT1aR and its ability to antago-
nize angiotensin II effects. The same BRET approach
used for hAPJ was used in HEK293T cells that coex-
pressed AT1-Rluc and b-arrestin 2-YFP. In these cells,
angiotensin II dose-dependently induced b-arrestin 2
recruitment toAT1aRwith an EC50 of 246 1.43 10
29M,
whereas protamine was inactive at modifying BRET
levels (Supplemental Fig. 5A, B); however, protamine
was unable to antagonize b-arrestin 2-YFP transloca-
tion to AT1aR induced by angiotensin II (Supplemental
Fig. 5C).
Antagonist activity of protamine can be
reversed by heparin
Protamine sulfate, which possesses a high affinity for
heparin, is routinely used in clinic after heart surgery to
reverse the anticlotting effects of heparin. Consequently,
we assumed that heparin could inhibit the antagonist ac-
tivity of protamine on APJ. To validate our hypothesis,
we first studied the intrinsic agonistic activity of heparin
and its effect on apelin-stimulating hAPJ. By using the
previouslydescribedBRETassay,we showed thatheparin
did not induce b-arrestin 2 recruitment to hAPJ (Fig. 3A).
Furthermore, it did not inhibit b-arrestin 2 recruitment to
hAPJ induced by apelin (Fig. 3B). Consequently, we next
tested the effect of heparin on protamine antagonizing
apelin activity. For this purpose, real-time BRET moni-
toring of b-arrestin 2-YFP recruitment to hAPJ-Rluc was
realized in HEK293T cells. By using this approach, we
demonstrated that protamine did not induce b-arrestin 2
translocation to hAPJ over time but instead fully inhibited
apelin activity when apelin was added few minutes later.
Surprisingly, injection of heparin after apelin immediately
reversed antagonist activity of protamine. As a result,
apelin that was present in the medium can bind hAPJ and
induced b-arrestin 2-YFP translocation (Fig. 3C). More-
over, our data demonstrate that the reverse activity of
heparin on protamine is dose-dependent (Fig. 3D). Ac-
cordingly, our results clearly show that protamine can
antagonize APJ activation, and this effect can be reversed
by heparin, which can release protamine that is bound
to APJ.
Antiangiogenic and antitumor activities of
protamine are mediated via antagonism of APJ
Since the early 1980s, protamine has been described as a
potent inhibitor of angiogenesis in vitro and in vivo as well
as in differentmousemodels of cancer (49, 50). Of interest,
this antiangiogenic activity is fully prevented by hepa-
rin cotreatment (50). Regarding angiogenesis, the role
of apelin signaling is well documented. This angio-
genic peptide plays a crucial role in both physiologic and
pathophysiologic angiogenesis, such as tumor neo-
vascularization (25, 34, 36, 38, 40); therefore, we evalu-
ated whether protamine could inhibit apelin-induced
angiogenesis in the CAM assay system. In this experi-
mental model, we show that apelin induced a strong
increase in vessel density and a reduction of the inter-
capillary space similar to that obtained with VEGF.
Conversely, protamine applied alone on the CAM did
not modify vessel density compared with control. Of
interest, protamine inhibited apelin-induced angiogen-
esis, whereas it did not alter the angiogenic effect of
VEGF (Fig. 4A, B).
To further examine the activity of protamine on tumor
growth induced by apelin, a syngeneic mouse tumor
model was developed by using TS/A mammary carci-
nomacells that stablyoverexpressedapelin (TS/A-apelin).
As previously described, these cells do not express APJ,
and apelin overexpression accelerates in vivo tumor
growth by inducing tumor neoangiogenesis (34). TS/
A-apelin cells were implanted subdermally into the
flanks of BALB/c mice and animals were then treated
subcutaneously with protamine or saline twice per
day. During the early stage of tumor development,
of APJ/ b-arrestin 2-GFP intracellular clusters induced by apelin 13 (10 nM) in U2OS cells that expressed APJ and b-arrestin
2-GFP. Data represent means 6 SEM of 2 independent experiments (C, D) or are representative of 6 (A) and 2 (B) independent
experiments. E) Protamine displaces binding of [125I]-apelin 13 (0.5 nM) to APJ in a dose-dependent manner. Results were
analyzed by nonlinear regression on a pooled data set from 2 independent experiments, assuming a model with 1-site competitive
binding (GraphPad Prism 5.0). F) GPCR profiling panel for protamine. Antagonist activity of protamine was assessed on different
Gq- and Gi/o-coupled receptors. Data represent means 6 SEM of 3 independent experiments. AGTR1, angiotensin II receptor
type 1; AVPR1A, arginine vasopressin receptor 1 A; CHRM1, cholinergic receptor muscarinic 1; CNR1, cannabinoid receptor 1;
CXCR4, C-X-C chemokine receptor type 4; EDNRA, endothelin receptor type A; GRM1, glutamate metabotropic receptor 1;
OXTR, oxytocin receptor.
protamine significantly reduced the accumulated
tumor burden per animal by 50% (Fig. 4C). However,
the protamine-induced decrease of tumor develop-
ment disappeared in the later stages, and a regrowth of
the protamine-treated tumors was observed. Of im-
portance, this activity of protamine on tumor growth
did not depend on the drug administration route as
the same effects were observed after intravenous in-
jection of protamine (Supplemental Fig. 6).
Protamine inhibits in vivo glucose tolerance
and vasodilatation induced by apelin, and its
activity is reversed by heparin
To show that protamine also inhibits apelin effects in vivo,
wenext analyzedprotamine activity onglucoseutilization
and vasodilatation induced by apelin. As previously de-
scribed during an oral glucose tolerance test (8), ampli-
tude of hyperglycemic responsewas significantly reduced
Figure 2. Antagonist activity of
protamine on intracellular re-
sponses induced by apelin. A)
Intrinsic activity of protamine
on Gi/o activation via APJ.
U2OS cells that stably expressed
hAPJ and b-arrestin 2-GFP were
stimulated with protamine in
the presence of forskolin
(20 mM). cAMP production was
normalized to the percentage
of forskolin-stimulated cAMP
accumulation (set at 100%). B)
Dose-response curve of prot-
amine for blocking adenylyl
cyclase inhibition induced by
apelin 13 (10 nM) in the pres-
ence of forskolin (20 mM). C)
Apelin 13 (100 nM) promotes
time-dependent phosphoryla-
tion of p42/p44 ERKs and Akt
proteins in U2OS cells that
stably expressed hAPJ and
b-arrestin 2-GFP. D) Protamine
pretreatment (1 mM) inhibits
ERKs and Akt phosphorylation
induced by apelin 13 (100 nM)
in the U2OS cells that expressed
hAPJ and b-arrestin 2-GFP.
E ) Real-time measurement of
b-arrestin 2 recruitment to APJ
measured by BRET in HEK293T
cells that expressed hAPJ-Rluc
and b-arrestin 2-YFP after addi-
tion, at time 0, of 1 mM apelin 13
(n) or PBS (O). As a negative
control, similar experiments
were carried out on cells that
transiently expressed only Rluc-
tagged hAPJ. F, G) Dose-
response curve of apelin 13 (F)
or protamine (G) for b-arrestin 2
recruitment to APJ measured by
BRET in HEK293T cells that
transiently coexpressed hAPJ-
Rluc and b-arrestin 2-YFP. H)
Protamine dose-dependently in-
hibits b-arrestin 2 recruitment
to APJ induced by apelin 13
(100 nM). Data are expressed
as the percentage of the maxi-
mal BRET signal obtained in
HEK293T cells that transiently
coexpressed Rluc-tagged hAPJ
and YFP-tagged b-arrestin 2 stim-
ulated with apelin 13 at 100 nM
(100%). Data represent means 6 SEM of 5 (A, B), 21 (F), 6 (G), and 4 (H) independent experiments or are representative of 1
experiment performed 3 times independently (C, D, E).
pressure, reaching 222 6 3.8 mmHg at approximately
1.0–1.5min after treatment,without changing heart rate
(data not shown). This apelin effect was blunted when
animals were pretreated with protamine (Fig. 6),
whereas protamine did not modify blood pressure by
itself (Supplemental Fig. 8). As our previous results
demonstrate that heparin can reverse antagonist activ-
ity of protamine on APJ in vitro (Fig. 3C, D), we next
evaluated the effect of heparin on the antagonism me-
diated by protamine on the hypotensive effect of apelin.
For this purpose, heparin was coinjected with prot-
amine a few minutes before apelin treatment. Whereas
heparin alone or heparin plus protamine did not mod-
ify mean arterial pressure (Supplemental Fig. 8), heparin
fully counteracted protamine antagonist activity, thereby
restoring the hypotensive effect of apelin (Fig. 6).
DISCUSSION
By using an original fluorescence-based, high-throughput
screening on the basis of the ability of APJ to internalize
Figure 3.Heparin reverses antagonist activity of protamine on APJ. A) Dose-response curve (U/100 ml) of heparin for b-arrestin 2
recruitment to APJ was measured by BRET in HEK293T cells that transiently coexpressed APJ-Rluc and b-arrestin 2-YFP. B)
Heparin (10 U/100 ml) does not modify apelin 13–induced b-arrestin 2 recruitment to APJ in HEK293T cells that expressed APJ-
Rluc and b-arrestin 2-YFP and measured by BRET. C) Real-time measurement of BRET signal in HEK293T cells that coexpressed
APJ-Rluc and b-arrestin 2-YFP after addition of protamine (100 mM) at time 0, followed by injection of apelin 13 (1 mM) at time
200 s. Heparin (10 U/100 ml) was added 200 s later. D) Heparin dose-dependently reverses antagonist activity of protamine
(1 mM) on b-arrestin 2 recruitment to APJ induced by apelin 13 (100 nM). Data are presented as the percentage of the maximal
inhibition obtained with protamine. Data represent means 6 SEM of 3 (A), 6 (B), and 4 (D) independent experiments each
performed in duplicate or are representative of 1 experiment performed 3 times independently (C).
when animals received an intravenous injection of 
200 pmol/kg of apelin compared with saline-treated mice 
(Fig. 5). Whereas protamine alone had no significant effect 
on glycemia, it clearly abrogated apelin effects. Of interest, 
neither apelin, protamine, nor a combination of protamine 
and apelin altered plasma insulin levels, which suggested 
that none of these treatments has any effect on insulin 
secretion (Supplemental Fig. 7).
In addition to its beneficial effect on glucose ho-
meostasis, systemic administration of apelin lowers 
arterial blood pressure via activation of APJ expressed 
by endothelial cells (24). We thus assessed protamine 
effects on apelin-induced vasodilatation in mice. Anes-
thetized animals were injected i.v with the different 
compounds via the femoral vein, and arterial blood 
pressure was monitored over time. Whereas vehicle 
injection of 0.9% saline revealed no change in blood 
pressure (Supplemental Fig. 8), angiotensin II elicited 
an immediate increase in mean arterial pressure, with a 
maximum of 37.3 6 5.3 mmHg, 1 min after its injection 
(Fig. 6). Conversely, administration of apelin induced a 
transient and significant decrease in mean arterial
with GFP-tagged b-arrestin 2, we report here the isolation
of a new antagonist of APJ, protamine, which displays an
affinity of 390 nM for hAPJ. Whereas protamine has no
intrinsicactivityonb-arrestin recruitment tohAPJanddoes
not activateAkt or ERKs, it acts as an inverse agonist on the
Gi/o pathway. Conversely, protamine behaves as a full
antagonist, inhibiting these different signaling pathways
with comparable IC50 values. Such antagonist effects of
protamine were also confirmed in vivo on apelin-induced
vasodilatation and glucose tolerance. Of interest, APJ
blockade was fully and swiftly reversed after heparin ad-
ministration both in vitro and in vivo.
To date, few APJ antagonists have been identified. The
peptide analog, apelin F13A, was first described to inhibit
apelin 13–induced decrease in blood pressure and
splanchnic neovascularization (48, 51); however, apelin
F13Acanalsobehaveas anAPJ agonist ondifferent in vitro
functional assays (1). Another peptide, MM54, is a com-
petitive antagonist of hAPJ, with a Ki of 82 nM, and does
not bind toAT1aR (42); however, unlike protamine,which
has been clinically approved by the FDA, the efficacy of
MM54 remains to be established in human patients.
At the chemical level, protamine is an arginine-rich
basic protein, similar to the compound ALX 40-4C, a
polypeptide of 9 arginine residues, which behaves as an
hAPJ antagonist in the micromolar range (43). Of interest,
poly-D-lysine, which possesses a similar structure and
charge density comparedwith protamine, does not inhibit
Figure 4. Antiangiogenic and antitumor activity of protamine is mediated via antagonism of APJ. A) Images of representative
CAMs for each condition [PBS, top; VEGF165 (500 ng), middle; apelin 13 (50 ng), bottom] are shown in the absence (left) or
presence of protamine (15 mg; right). Blood vessels (green) are visualized by using fluorescein-labeled S. nigra lectin. B)
Angiogenic activity of apelin and VEGF and antiangiogenic activity of protamine were quantified by measuring the surface of
avascular zones in the CAM assay. Data represent means 6 SEM of 20 (control, apelin, and VEGF + protamine), 15 (VEGF and
protamine alone), and 25 (apelin + protamine) CAMs. Statistical significance was assessed by using 1-way ANOVA followed by
Bonferroni posttest. **P , 0.01. C) Effect of subcutaneous injection of protamine (5000 U/kg) twice per day on tumor
volume (TS/A tumor cell line overexpressing apelin) compared with saline solution–treated mice. Tumor volume on days
(D) 10 and 21 are presented. Statistical significance was assessed by using unpaired Student’s t test. **P , 0.01; n = 17 animals
per group.
hAPJ stimulationbyapelin,which suggests thatbinding to
hAPJ and activity of protamine do not rely on its positive
charges. However, like ALX 40-4C, which antagonizes
C-X-C chemokine receptor type 4 in the nanomolar range,
protamine also inhibits SDF-1a activity on this receptor in
vitro; therefore, theantiangiogenic andantitumoractivities
of protamine could rely on antagonism at both APJ and
CXCR4. However, more experiments are needed to con-
firm the involvement of CXCR4 in protamine effects
in vivo.
Given the structural relationship between APJ and
AT1aR (2, 3), it should be noted that protamine alone does
not activate angiotensin receptor, nor does it inhibit its
stimulation by angiotensin II. Surprisingly, protamine has
been observed to bind fibroblast growth factor and
platelet-derived growth factor tyrosine kinase receptors
and inhibit their mitogenic activity in endothelial and
fibroblast cells, respectively (52, 53); however, even a 100-
fold molar excess of protamine does not impair basic fi-
broblast growth factor mitogenic activity in endothelial
cells (53). Regarding platelet-derived growth factor re-
ceptors, thepreciseKi valueandefficacyofprotaminehave
not been evaluated by Huang and collaborators (52).
At the clinical level, the first clinical indication of prot-
amine is to reverse the anticlotting action of heparin.
Thiseffect reliesondirect interactionbetween the2proteins
via opposite charges. Conversely, our results demon-
strate that heparin can also reverse the effects of protamine,
even when it is bound to the receptor, which suggests
that the interaction between heparin and protamine in-
volves regions of protamine that are still accessible.
Several decades ago, protamine was described as an
antiangiogenic molecule that was able to reduce vascular
density and tumor growth in different mouse models of
cancer (49, 50). In addition, such an antitumor effect has
also been reported in patients with advanced carcinoma
(54). These properties are confirmed in our syngeneic
apelin-overexpressing mouse tumor model, TS/A-apelin,
where protamine reduced the accumulated tumor burden
in the early stages of tumor development. Of interest,
prolonged treatment of animals revealed a regrowth of
protamine-treated tumors. Such a resistance is similar to
that observed with antiangiogenic treatments, such as
antibodies that target either VEGF receptor (55) or VEGF
with bevacizumab (avastin) as monotherapy in a clinical
trial (56). This effect is explained by activation of other
angiogenic pathways to circumvent the blockade of the
targeted pathway (55). One possible angiogenic candidate
would be the VEGF pathway, given that protamine is in-
effective at inhibiting its proangiogenic activity in the
CAM assay. In addition to its action on tumor neoangio-
genesis, protamine could also target apelin signaling
function at the tumor cell level. Indeed, as apelin and APJ
are expressed by human carcinoma cells, apelin can pro-
mote their survival and proliferation (35–37); however, in
our mouse TS/A tumor model, the activity of protamine
was only analyzed on tumor angiogenesis and not in
Figure 5. Protamine inhibits apelin-induced glucose tolerance.
Oral glucose tolerance test in mice denied food for 6 h that
were intravenously treated with saline (black curve, n = 8),
apelin 13 (200 pmol/kg; red curve, n = 5), protamine (10 U/kg),
and apelin 13 (200 pmol/kg; blue curve, n = 7), or with
protamine alone (10 U/kg; orange curve, n = 5) 30 min before
oral glucose (3 g/kg) load (time 0). Blood was collected from
the tail vein at 230, 0, 15, 45, 30, 60, 90, and 120 min, and
glycemia was measured on these samples. Each point shows
the mean 6 SEM of the described number of mice. Data
were analyzed by using 1-way ANOVA repeated measurements.
***P , 0.001, apelin vs. saline solution; #P , 0.05, apelin vs.
protamine; 3P , 0.05, apelin vs. protamine + apelin.
Figure 6. Protamine inhibits apelin-induced
vasodilatation, and its activity can be reversed
by heparin. Time-dependent changes of arterial
blood pressure after intravenous administration at
time 0 of saline (black curve, n = 5); angiotensin II
(35 ng/kg; green curve, n = 5); apelin 12
(100 nmol/kg; red curve, n = 5); protamine
(700 U/kg) and apelin 12 (100 nmol/kg;
blue curve, n = 5); and heparin (1400
U/kg), protamine (700 U/kg), and apelin 12
(100 nmol/kg; gray curve, n = 5). Data
represent means 6 SEM. Statistical significance
between groups was assessed by using 2-way
ANOVA followed by Bonferroni posttest.
*P , 0.05, **P , 0.01, ***P , 0.001, angiotensin
vs. saline solution; #P , 0.05, ##P , 0.01,
###P , 0.001, apelin vs. saline solution;
†P , 0.05, ††P , 0.01, protamine + apelin vs.
apelin; 3P , 0.05, 33P , 0.01, heparin +
protamine + apelin vs. protamine + apelin.
tumor cells as this cell linewas reported to not expressAPJ
(34). Accordingly, it is likely that protamine effects on tu-
mor growth are underestimated in the results presented
here.
In addition to counteracting the anticlotting effects of
heparin after cardiac surgery, protamine has side effects
that lead to increased pulmonary artery pressure second-
ary to pulmonary vasoconstriction. Of interest, patients
with pulmonary hypertension display a significant re-
duction of serum apelin levels compared with healthy
controls (28), together with a down-regulation of apelin
expression in pulmonary arterial endothelial cells (57).
Moreover, apelin-null mice develop more severe pulmo-
nary hypertension compared with wild-type mice when
exposed to chronic hypoxia (28). Thus, it is likely that
pulmonary hypertension induced by protamine in clinic
mayalso relyon the inhibitionofAPJ. Further experiments
will be necessary to assess the potency of apelin to reverse
this adverse effect of protamine.
Altogether, our data reveal a new pharmacologic prop-
ertyofprotamine, theblockadeofAPJ,whichcouldexplain
some side effects that have been observed in protamine-
treated patients, and a new clinical indication, an
antiangiogenic activity for treating neoangiogenesis-
dependent diseases and cancer.
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